

Although the use of biosimilars is still quite heterogeneous across EU countries, their use is increasing as more become available and more experience is acquired with their use. Clearly, biosimilars are being established as a good tool to reduce health care expenditure in the use of expensive biologics for many chronic indications.

REFERENCES

- Ayyar VS. (2011) History of growth hormone therapy. *Indian Journal of Endocrinology and Metabolism* **15(Suppl. 3)**, S162–S165. Available from: <http://www.ema.europa.eu/ema/> (Accessed July 28, 2015).
- Ebbers HC, Crow SA, Vulto AG, et al. (2012) Interchangeability, immunogenicity and biosimilars. *Nature Biotechnology* **30**, 1186–1190.
- EC. (2003) Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. *Official Journal of the European Union L* **159**, 46–94.
- EC. (2004) Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. *Official Journal of the European Union L* **136**, 34–57.
- EC. (2010) Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. *Official Journal of the European Union L* **276**, 33–79.
- EMA. (2003) Note for guidance on biotechnological/biological products subject to changes in their manufacturing process (CPMP/ICH/5721/03). European Medicines Agency, London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002805.pdf (Accessed July 28, 2015).
- EMA. (2010) Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use (EMA/CHMP/BMWP/86289/2010). European Medicines Agency, London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf (Accessed July 29, 2015).
- EMA. (2012) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) (EMA/CHMP/BWP/247713/2012). European Medicines Agency, London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf (Accessed July 28, 2015).
- EMA. (2013) Assessment report: Remsima. European Medicines Agency, Committee for Medicinal Products for Human Use, London, UK. EMA/CHMP/589317/2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf (Accessed July 29, 2015).
- EMA. (2014) Guideline on similar biological medicinal products (CHMP/437/04 Rev 1). European Medicines Agency, London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf (Accessed July 28, 2015).
- EMA. (2015) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMA/CHMP/BMWP/42832/2005 Rev1). European Medicines Agency, London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf (Accessed July 28, 2015).
- EMA. (2006) Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (EMA/CHMP/BMWP/14327/2006). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf (Accessed July 29, 2015).